baccarat70ml| Zixin Pharmaceutical's (002118) investor claim case has been submitted to the court for filing

May 11, 2024Baccarat70mlZixin Pharmaceutical (002118) false statement investor claim case represented by Xu Feng of Shanghai Jiucheng Law firm has been filed with Changchun Intermediate people's Court and is currently waiting for the court's review arrangement. at the same time, the legal team is still continuing to promote the filing of the follow-up case and continue to accept it.Baccarat70mlHis investor's claim entrustment. (lawyer Xu Feng's column)

On April 10, 2024, Zixin Pharmaceutical (002118) issued a notice on the receipt of administrative penalties and advance notice of market prohibition. Verified by the Jilin Regulatory Administration of the Securities Regulatory Commission, Zixin Pharmaceutical is suspected of violating the law as follows:

First, Zixin Pharmaceutical's annual report from 2013 to 2020 failed to disclose related party transactions in accordance with the regulations, resulting in major omissions in Zixin Pharmaceutical's annual report.

2. From 2014 to 2020, Zixin Pharmaceutical falsely increased the purchasing cost of ginseng under the forest, and carried forward the cost of inventory with the purchasing cost, resulting in false records in the annual report from 2014 to 2020 and failure to disclose non-operating capital transactions in accordance with the regulations. Zixin Pharmaceutical is suspected of falsely increasing the purchasing cost of ginseng under the forest from 2014 to 2020. As of the time of investigation, the company has not corrected the above behavior.

Third, Zixin Pharmaceutical Co., Ltd. falsely increased its income and profits in 2017 and 2018 through fraud, resulting in false records in its annual reports in 2017 and 2018.

Fourth, Zixin Pharmaceutical Company failed to disclose the illegal guarantee for related parties in accordance with the regulations.

5. Zixin Pharmaceutical Company failed to disclose major litigation matters in accordance with the regulations.

Lawyer Xu Feng, director of Shanghai Jiucheng Law firm, believes that based on the current illegal facts, according to the provisions of the Securities Law, it is tentatively scheduled to buy Zixin Pharmaceutical shares between February 25, 2014 and January 6, 2023. Investors who sell or continue to hold shares after January 6, 2023 can also file claims. (* ST Zixin rights protection entrance)

(this article is contributed by lawyer Xu Feng, director of Shanghai Jiucheng Law firm, and does not represent Sina's financial position. Lawyer Xu Feng, who has been a lawyer since 2008, has been a claim agent in the field of securities fraud, such as misrepresentation, insider trading, market manipulation and so on. Over the past ten years, investors who have represented nearly 200 stocks have won the case or obtained compensation through mediation, and in the same period, they have also won or mediated claims for nearly 300 stocks within the limitation of action, and some of them have already won the case and obtained compensation through mediation. License No.: 13101200810965495)